Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Liabilities and Shareholders Equity: 2021-2025

Historic Liabilities and Shareholders Equity for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Liabilities and Shareholders Equity rose 26.24% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 26.24%. This contributed to the annual value of $1.1 billion for FY2024, which is 29.02% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Liabilities and Shareholders Equity is $1.2 billion, which was up 8.93% from $1.1 billion recorded in Q2 2025.
  • Krystal Biotech's 5-year Liabilities and Shareholders Equity high stood at $1.2 billion for Q3 2025, and its period low was $443.0 million during Q1 2021.
  • In the last 3 years, Krystal Biotech's Liabilities and Shareholders Equity had a median value of $917.7 million in 2024 and averaged $917.0 million.
  • Per our database at Business Quant, Krystal Biotech's Liabilities and Shareholders Equity decreased by 13.78% in 2023 and then soared by 60.44% in 2024.
  • Krystal Biotech's Liabilities and Shareholders Equity (Quarterly) stood at $626.3 million in 2021, then dropped by 10.83% to $558.5 million in 2022, then skyrocketed by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024, then grew by 26.24% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.2 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.